LINQ for impEdance meAsuremeNt While Off From HF Medication Study
Status:
Unknown status
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this non-randomized, cross-over, unblinded, single-center feasibility study is
to assess the sensitivity of the LINQ ICM to measure derived-subcutaneous impedance in
patients with heart failure during periods when diuretics and/or HF-medication consumption is
increased or suspended for 48 hours (up to 72 hours at physician discretion) and to collect
safety information related to HF status and to medication consumption changes.